Altretamine for the Treatment of Metastatic Renal Cell Carcinoma – A Hoosier Oncology Group Trial

Authors: Zon R.T.¹; McClean J.²; Helman D.³; Ansari R.¹; Picus J.⁴; Sandler A.³; Williams S.D.³; Loehrer Sr. P.J.⁵

Source: Investigational New Drugs, Volume 19, Number 3, August 2001 , pp. 229-231(3)

Publisher: Springer

Buy & download fulltext article:

Price: $47.00 plus tax (Refund Policy)

Abstract:

Thirty patients with advanced renal cell carcinoma were treated on a phase 11 trial with altretamine. Altretamine was administered orally at a dosage of 260 mg/m² days 1 through 14 with cycles repeated every 28 days. Nausea and vomiting were the most common toxicities. Ten percent (3 of 30) experienced Grade 3 gait abnormalities. None of the thirty evaluable patients achieved a complete or partial response. In summary, altretamine did not show antitumor activity in the treatment of advanced renal cell carcinoma.

Keywords: altretamine; renal cell carcinoma

Language: English

Document Type: Regular paper

Affiliations: 1: Northern Indian Cancer Research Consortium, South Bend, IN, USA 2: The Cottage Professional Building, Galesburg, USA 3: Indiana University Cancer Center, Indianapolis, USA 4: Washington University/Barnard Cancer Center, St. Louis, MO, USA 5: Indiana University Cancer Center, Indianapolis, USA; The Walther Oncology Institute, Indianapolis, IN, USA

Publication date: 2001-08-01